mass spectrometric immunoassay

The proteomics firm is swapping 4 million of its shares for a 10 percent interest in CPR with the goal of moving into clinical trials and related research.

In Life Sciences, CEO Thomas Joyce noted a strong performance by Beckman Coulter, while in Diagnostics, he said Cepheid grew 25 percent year over year. 

The new European initiative promises to deliver multiple new tests and methods for improving the treatment of breast cancer and rectal cancer.

Carrier screens for cystic fibrosis, fragile X syndrome, and spinal muscular atrophy detected carrier status in one in 20 individuals and led to diagnoses in seven pregnancies.

Bioage Labs now intends to set up an internal laboratory to experiment with different compounds, while building out its team.

Announced during the company's recent analyst day, the instrument could mark a major step in mass spectrometry's ongoing move into clinical applications.

After years of technical setbacks and challenges, mass spec-based clinical proteomics is "ready for prime time," a Thermo Fisher Scientific researcher told ProteoMonitor this week.

Thermo Fisher Scientific last week announced a collaboration with German diagnostics firm Immundiagnostik for development of mass spec-based assays for protein and peptide quantitation.

Thermo Fisher Scientific said this week that it has acquired protein biomarker firm Intrinsic Bioprobes, adding to its clinical proteomics portfolio.


The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.